Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine.

Subjects > or = 55 years of age were immunized with attenuated varicella zoster virus (VZV) vaccine (live) or with the same vaccine, which had been heated to 56 degrees C for 7 days (killed). The ability of subjects' blood lymphocytes to lyse target cells infected with VZV was determined before and 3 months after immunization using autologous Epstein-Barr virus (EBV) lymphoblasts as targets for human leukocyte antigen (HLA) class I restricted cytotoxicity and human fibroblasts as targets for unrestricted (natural killer [NK]) cytotoxicity. The live vaccine recipients showed an increase in their class I-restricted lysis of targets compared with the recipients of the killed vaccine. The two populations showed equivalent increase in their NK-dependent lysis of fibroblast targets. The results support the view that both the live and killed vaccines stimulate cytotoxicity by VZV-specific lymphocytes but that the live vaccine stimulates relatively more class I-restricted killing.

[1]  S. Plotkin.  Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. , 1994, Science.

[2]  R. Mahalingam,et al.  Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones , 1992, Journal of virology.

[3]  F. Hayden,et al.  Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. , 1992, Antiviral research.

[4]  P. Campbell,et al.  Macrophages as accessory cells for class I MHC-restricted immune responses. , 1991, Journal of immunology.

[5]  R. Burger,et al.  Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs , 1991, Journal of virology.

[6]  P. Kinchington,et al.  Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. , 1991, Journal of immunology.

[7]  M. Levin,et al.  Processing and presentation of cell-associated varicella-zoster virus antigens by human monocytes. , 1987, Clinical and Experimental Immunology.

[8]  M. Levin,et al.  Specific lysis of varicella zoster virus-infected B lymphoblasts by human T cells , 1986, Journal of virology.

[9]  S. Plotkin,et al.  Antibody-dependent cell-mediated cytotoxicity against varicella-zoster virus-infected targets , 1982, Infection and immunity.

[10]  L. Melton,et al.  Population‐Based Study of Herpes Zoster and Its Sequelae , 1982, Medicine.

[11]  H. Ertl,et al.  An Analysis of Effector T Cell Generation and Function in Mice Exposed to Influenza A or Sendai Viruses , 1981, Immunological reviews.

[12]  M. Levin,et al.  Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. , 1994, Viral immunology.

[13]  R. Germain,et al.  The biochemistry and cell biology of antigen processing and presentation. , 1993, Annual review of immunology.

[14]  J. F. Young,et al.  Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. , 1992, Vaccine.

[15]  A. Hayward,et al.  Cellular interactions in the lysis of varicella-zoster virus infected human fibroblasts. , 1986, Clinical and experimental immunology.